JP2002516282A5 - - Google Patents

Download PDF

Info

Publication number
JP2002516282A5
JP2002516282A5 JP2000550487A JP2000550487A JP2002516282A5 JP 2002516282 A5 JP2002516282 A5 JP 2002516282A5 JP 2000550487 A JP2000550487 A JP 2000550487A JP 2000550487 A JP2000550487 A JP 2000550487A JP 2002516282 A5 JP2002516282 A5 JP 2002516282A5
Authority
JP
Japan
Prior art keywords
treatment
component
pharmaceutical composition
effective amount
severe depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000550487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/011276 external-priority patent/WO1999061027A1/en
Publication of JP2002516282A publication Critical patent/JP2002516282A/ja
Publication of JP2002516282A5 publication Critical patent/JP2002516282A5/ja
Pending legal-status Critical Current

Links

JP2000550487A 1998-05-22 1999-05-21 難治性鬱病の処置のための組合せ治療 Pending JP2002516282A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22
US60/086,444 1998-05-22
PCT/US1999/011276 WO1999061027A1 (en) 1998-05-22 1999-05-21 Combination therapy for treatment of refractory depression

Publications (2)

Publication Number Publication Date
JP2002516282A JP2002516282A (ja) 2002-06-04
JP2002516282A5 true JP2002516282A5 (enExample) 2006-07-06

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000550487A Pending JP2002516282A (ja) 1998-05-22 1999-05-21 難治性鬱病の処置のための組合せ治療

Country Status (24)

Country Link
EP (1) EP0958824A3 (enExample)
JP (1) JP2002516282A (enExample)
KR (1) KR20010043730A (enExample)
CN (1) CN1154496C (enExample)
AU (1) AU761510B2 (enExample)
BR (1) BR9911049A (enExample)
CA (1) CA2332814C (enExample)
CZ (1) CZ20004279A3 (enExample)
EA (1) EA004539B1 (enExample)
HK (1) HK1040055B (enExample)
HR (1) HRP20000797A2 (enExample)
HU (1) HUP0101901A3 (enExample)
ID (1) ID26861A (enExample)
IL (1) IL139592A (enExample)
MY (1) MY127938A (enExample)
NO (1) NO20005885L (enExample)
NZ (1) NZ507980A (enExample)
PL (1) PL344331A1 (enExample)
SK (1) SK17512000A3 (enExample)
TR (1) TR200003443T2 (enExample)
TW (1) TWI226829B (enExample)
UA (1) UA78181C2 (enExample)
WO (1) WO1999061027A1 (enExample)
ZA (1) ZA200006815B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
SI1237553T1 (sl) * 1999-12-06 2006-06-30 Lundbeck & Co As H Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
AU2003295235B2 (en) 2002-12-27 2008-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
AU2004283196B2 (en) 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005056056A2 (en) * 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2439201B1 (en) 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
HRP20141008T1 (hr) * 2007-02-09 2015-01-02 Alphapharm Pty Ltd Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP2000506859A (ja) * 1996-03-11 2000-06-06 イーライ・リリー・アンド・カンパニー 双極性障害の処置方法
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Similar Documents

Publication Publication Date Title
JP2002516282A5 (enExample)
Vulink et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.
US4777173A (en) Method for treatment of alcohol abuse
Biri et al. Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study
Farlow Pharmacokinetic profiles of current therapiesfor Alzheimer's disease: implications for switching to galantamine
JP2007512371A5 (enExample)
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
JP2013544850A5 (enExample)
SK14612003A3 (sk) Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
Walsh et al. The pharmacologic treatment of eating disorders
JP2003504332A5 (enExample)
Lauerma Successful treatment of citalopram‐induced anorgasmia by cyproheptadine
DeBattista et al. Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs
Crow Treatment of binge eating disorder
BRPI0713733A2 (pt) métodos para diminuir os sintomas de depressão e para tratar uma ou mais condições psicológicas, composição farmacêutica e kit
WO2004096118A3 (en) Composition for improving cognition and memory
Khawaja et al. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
WO2002039879A3 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
JP2003522112A5 (enExample)
JP2007505156A5 (enExample)
JP2002530341A5 (enExample)